- Home
- IMTX vs SANA Comparison
IMTX vs SANA Comparison
Compare IMTX & SANA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMTX
- SANA
- Stock Information
- Founded
- IMTX N/A
- SANA 2018
- Country
- IMTX Germany
- SANA United States
- Employees
- IMTX N/A
- SANA N/A
- Industry
- IMTX Biotechnology: Biological Products (No Diagnostic Substances)
- SANA Medicinal Chemicals and Botanical Products
- Sector
- IMTX Health Care
- SANA Health Care
- Exchange
- IMTX Nasdaq
- SANA Nasdaq
- Market Cap
- IMTX 865.5M
- SANA 983.4M
- IPO Year
- IMTX N/A
- SANA 2021
- Fundamental
- Price
- IMTX $9.39
- SANA $4.16
- Analyst Decision
- IMTX Strong Buy
- SANA Strong Buy
- Analyst Count
- IMTX 5
- SANA 6
- Target Price
- IMTX $15.00
- SANA $8.00
- AVG Volume (30 Days)
- IMTX 800.4K
- SANA 3.7M
- Earning Date
- IMTX 11-17-2025
- SANA 11-07-2025
- Dividend Yield
- IMTX N/A
- SANA N/A
- EPS Growth
- IMTX N/A
- SANA N/A
- EPS
- IMTX N/A
- SANA N/A
- Revenue
- IMTX $152,823,253.00
- SANA N/A
- Revenue This Year
- IMTX N/A
- SANA N/A
- Revenue Next Year
- IMTX N/A
- SANA N/A
- P/E Ratio
- IMTX N/A
- SANA N/A
- Revenue Growth
- IMTX 83.61
- SANA N/A
- 52 Week Low
- IMTX $3.30
- SANA $1.26
- 52 Week High
- IMTX $11.40
- SANA $7.30
- Technical
- Relative Strength Index (RSI)
- IMTX 79.00
- SANA 69.92
- Support Level
- IMTX $6.90
- SANA $3.28
- Resistance Level
- IMTX $9.25
- SANA $3.58
- Average True Range (ATR)
- IMTX 0.46
- SANA 0.23
- MACD
- IMTX 0.27
- SANA 0.11
- Stochastic Oscillator
- IMTX 95.86
- SANA 95.35
About IMTX Immatics N.V.
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.
About SANA Sana Biotechnology Inc.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 and others.